Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders.
Harmony Biosciences Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$38.54|
|52 Week High||US$25.09|
|52 Week Low||US$52.74|
|1 Month Change||16.33%|
|3 Month Change||30.29%|
|1 Year Change||18.69%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||4.13%|
Recent News & Updates
Harmony Biosciences Holdings' (NASDAQ:HRMY) Promising Earnings May Rest On Soft Foundations
Harmony Biosciences Holdings, Inc. ( NASDAQ:HRMY ) just reported some strong earnings, and the market rewarded them...
|HRMY||US Pharmaceuticals||US Market|
Return vs Industry: HRMY exceeded the US Pharmaceuticals industry which returned 13.8% over the past year.
Return vs Market: HRMY underperformed the US Market which returned 36.2% over the past year.
Stable Share Price: HRMY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: HRMY's weekly volatility (7%) has been stable over the past year.
About the Company
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings Fundamentals Summary
|HRMY fundamental statistics|
Is HRMY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HRMY income statement (TTM)|
|Cost of Revenue||US$40.91m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.34|
|Net Profit Margin||7.30%|
How did HRMY perform over the long term?See historical performance and comparison
Is Harmony Biosciences Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HRMY ($38.54) is trading below our estimate of fair value ($248.69)
Significantly Below Fair Value: HRMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HRMY is poor value based on its PE Ratio (127.8x) compared to the US Pharmaceuticals industry average (22x).
PE vs Market: HRMY is poor value based on its PE Ratio (127.8x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: HRMY is poor value based on its PEG Ratio (2.9x)
Price to Book Ratio
PB vs Industry: HRMY is overvalued based on its PB Ratio (17.4x) compared to the US Pharmaceuticals industry average (3.2x).
How is Harmony Biosciences Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HRMY's forecast earnings growth (44.1% per year) is above the savings rate (2%).
Earnings vs Market: HRMY's earnings (44.1% per year) are forecast to grow faster than the US market (14.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: HRMY's revenue (30.8% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: HRMY's revenue (30.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HRMY's Return on Equity is forecast to be high in 3 years time
How has Harmony Biosciences Holdings performed over the past 5 years?
Last years revenue growth
Earnings and Revenue History
Quality Earnings: HRMY has a high level of non-cash earnings.
Growing Profit Margin: HRMY became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: HRMY has become profitable over the past 5 years.
Accelerating Growth: HRMY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: HRMY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: HRMY's Return on Equity (18.3%) is considered low.
How is Harmony Biosciences Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: HRMY's short term assets ($204.7M) exceed its short term liabilities ($36.6M).
Long Term Liabilities: HRMY's short term assets ($204.7M) exceed its long term liabilities ($196.5M).
Debt to Equity History and Analysis
Debt Level: HRMY's debt to equity ratio (154.6%) is considered high.
Reducing Debt: Insufficient data to determine if HRMY's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: HRMY's debt is well covered by operating cash flow (25.3%).
Interest Coverage: HRMY's interest payments on its debt are not well covered by EBIT (1.9x coverage).
What is Harmony Biosciences Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HRMY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HRMY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HRMY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HRMY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HRMY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Jacobs (53 yo)
Mr. John Charles Jacobs, MBA, serves as President and Chief Executive Officer of Harmony Biosciences, LLC. He serves as Director at Life Sciences Pennsylvania since May 6, 2021. He served as Chairman of Ha...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD3.23M) is about average for companies of similar size in the US market ($USD3.68M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: HRMY's management team is considered experienced (3 years average tenure).
Experienced Board: HRMY's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 635.5%.
Harmony Biosciences Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Harmony Biosciences Holdings, Inc.
- Ticker: HRMY
- Exchange: NasdaqGM
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.136b
- Shares outstanding: 57.01m
- Website: https://www.harmonybiosciences.com
Number of Employees
- Harmony Biosciences Holdings, Inc.
- 630 West Germantown Pike
- Suite 215
- Plymouth Meeting
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:09|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.